0.4799
price down icon9.81%   -0.0522
after-market After Hours: .47 -0.0099 -2.06%
loading
Jasper Therapeutics Inc stock is traded at $0.4799, with a volume of 242.01K. It is down -9.81% in the last 24 hours and down -17.39% over the past month. Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
See More
Previous Close:
$0.5321
Open:
$0.546
24h Volume:
242.01K
Relative Volume:
0.65
Market Cap:
$15.97M
Revenue:
Net Income/Loss:
$-55.73M
P/E Ratio:
-0.1487
EPS:
-3.2274
Net Cash Flow:
$-68.87M
1W Performance:
-15.84%
1M Performance:
-17.39%
6M Performance:
-50.32%
1Y Performance:
-80.65%
1-Day Range:
Value
$0.4778
$0.55
1-Week Range:
Value
$0.4601
$0.577
52-Week Range:
Value
$0.3151
$2.69

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name
Name
Jasper Therapeutics Inc
Name
Phone
(650) 549-1400
Name
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Name
Employee
22
Name
Twitter
Name
Next Earnings Date
2026-11-09
Name
Latest SEC Filings
Name
JSPR's Discussions on Twitter

Compare JSPR vs VRTX, MRNA, REGN, ARGX, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
JSPR icon
JSPR
Jasper Therapeutics Inc
0.4799 15.97M 0 -55.73M -68.87M -3.2274
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-14-26 Resumed William Blair Outperform
Aug-12-26 Initiated Piper Sandler Overweight
May-15-26 Downgrade TD Cowen Buy → Hold
Mar-23-26 Resumed UBS Neutral
Jan-13-26 Initiated Rodman & Renshaw Buy
Jul-08-25 Downgrade BMO Capital Markets Outperform → Market Perform
Jul-08-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-07-25 Downgrade Cantor Fitzgerald Overweight → Neutral
Jul-07-25 Downgrade William Blair Outperform → Mkt Perform
Feb-13-25 Initiated UBS Buy
Dec-06-24 Initiated BMO Capital Markets Outperform
Sep-09-24 Initiated JMP Securities Mkt Outperform
Jul-08-24 Initiated BTIG Research Buy
Jun-27-24 Initiated Stifel Buy
May-06-24 Initiated H.C. Wainwright Buy
Apr-03-24 Initiated Evercore ISI Outperform
Mar-28-24 Initiated RBC Capital Mkts Outperform
Mar-18-24 Initiated TD Cowen Outperform
Aug-11-23 Initiated CapitalOne Overweight
Feb-28-22 Initiated Cantor Fitzgerald Overweight
Nov-08-21 Initiated Credit Suisse Outperform
Oct-21-21 Initiated William Blair Outperform
Oct-20-21 Initiated BMO Capital Markets Outperform
Oct-13-21 Initiated Oppenheimer Outperform
View All

Jasper Therapeutics Inc Stock (JSPR) Latest News

pulisher
Oct 09, 2026

Jasper Therapeutics, Inc. (JSPR) stock price, news, quote and history - Yahoo Finance Singapore

Oct 09, 2026
pulisher
Oct 07, 2026

All outstanding warrants are eligible for Jasper Therapeutics (JSPR)'s cash purchase offer. - Stock Titan

Oct 07, 2026
pulisher
Oct 07, 2026

About $4 million is the expected payout if holders turn in all their rights to buy Jasper shares. - Stock Titan

Oct 07, 2026
pulisher
Oct 07, 2026

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants - GlobeNewswire

Oct 07, 2026
pulisher
Oct 05, 2026

Jasper Therapeutics approves reverse split for Jasper Therapeutics stock - AD HOC NEWS

Oct 05, 2026
pulisher
Oct 05, 2026

Jasper Therapeutics Closes Kira Acquisition, $132M Financing; Pro Forma Cash $142.8M - Minichart

Oct 05, 2026
pulisher
Oct 05, 2026

Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split. - Stock Titan

Oct 05, 2026
pulisher
Oct 02, 2026

After closing roughly $132M in financing, Jasper Therapeutics (JSPR) reports illustrative combined losses. - Stock Titan

Oct 02, 2026
pulisher
Oct 01, 2026

Jasper Therapeutics Completes Kira Merger With $132 Million Private Placement - Minichart

Oct 01, 2026
pulisher
Oct 01, 2026

Form 8K Jasper Therapeutics Inc For: 1 October By Investing.com - Investing.com Canada

Oct 01, 2026
pulisher
Oct 01, 2026

Kira’s auditors cited going-concern doubt. Jasper Therapeutics (JSPR) adds its loss figures. - Stock Titan

Oct 01, 2026
pulisher
Sep 28, 2026

Jasper Therapeutics announces CFO resignation and interim appointments - Investing.com

Sep 28, 2026
pulisher
Sep 28, 2026

Jasper Therapeutics announces CFO resignation and interim appointments By Investing.com - Investing.com Nigeria

Sep 28, 2026
pulisher
Sep 28, 2026

Form 8K Jasper Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa

Sep 28, 2026
pulisher
Sep 28, 2026

Three interim appointments will follow the finance chief's departure at Jasper Therapeutics (JSPR). - Stock Titan

Sep 28, 2026
pulisher
Sep 27, 2026

Jasper Therapeutics stock gains 4.05 percent as vote nears - AD HOC NEWS

Sep 27, 2026
pulisher
Sep 24, 2026

Ten Jasper Therapeutics (JSPR) warrants are exercisable for one share as Nasdaq moves to remove their listing. - Stock Titan

Sep 24, 2026
pulisher
Sep 16, 2026

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments - Taiwan News

Sep 16, 2026
pulisher
Sep 15, 2026

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments - The Manila Times

Sep 15, 2026
pulisher
Sep 15, 2026

Jasper Therapeutics Appoints Senior Vice President of Regulatory Affairs and Vice President of Clinical Development - Quiver Quantitative

Sep 15, 2026
pulisher
Sep 09, 2026

A biotech company's New York talk will be webcast live - Stock Titan

Sep 09, 2026
pulisher
Sep 08, 2026

Jasper Therapeutics (NASDAQ: JSPR) Schedules September 30 Vote on Increasing Authorized Common Stock - Kalkine Media

Sep 08, 2026
pulisher
Sep 02, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Sep 02, 2026
pulisher
Aug 28, 2026

Jasper Therapeutics Inc (JSPRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 28, 2026
pulisher
Aug 27, 2026

Jasper Therapeutics Inc (JSPRW) Key Financial Ratios – Valuation, Profitability & More - Value Research

Aug 27, 2026
pulisher
Aug 26, 2026

Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning - Stock Titan

Aug 26, 2026
pulisher
Aug 22, 2026

Jasper (JSPR) Latest: Gains 3.59% to Reach $0.72 in Latest Trading; Price Levels: Price Remains Between $0.68 Support and $0.76 Resistance under the Current SnapshotLong Setup Ideas - vinanet.vn

Aug 22, 2026
pulisher
Aug 19, 2026

Wenru Song Net Worth (2026) - GuruFocus

Aug 19, 2026
pulisher
Aug 18, 2026

Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada

Aug 18, 2026
pulisher
Aug 17, 2026

Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com Australia

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com Canada

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com India

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com

Aug 17, 2026
pulisher
Aug 17, 2026

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com

Aug 17, 2026
pulisher
Aug 15, 2026

JSPR Q1 2026 Earnings: 91.94% EPS Beat Signals Cost Discipline, But Stock Slips 8.46%Earnings Season Preview - vinanet.vn

Aug 15, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative

Aug 14, 2026
pulisher
Aug 14, 2026

JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance

Aug 14, 2026

Jasper Therapeutics Inc Stock (JSPR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$6.58
price down icon 4.22%
$9.94
price down icon 3.21%
$5.53
price down icon 3.66%
$11.27
price down icon 6.16%
$18.60
price down icon 1.74%
WVE WVE
$3.13
price down icon 1.88%
Cap:     |  Volume (24h):